EXELIXIS, INC.
ALAMEDA, CA

Exelixis, Inc., known for its innovative contributions in oncology, is a company headquartered in Alameda, California. Incorporated on September 6, 2012, and initially filed in Delaware, the firm operates with a focus on developing therapies that provide hope for remission among cancer patients. Exelixis identifies primarily as a Foreign Profit Limited Partnership (FORP) and manages operations under the oversight of directors such as Alan M.D. Garber, David Johnson, and George Ph.D. Poste. The company's primary mailing address is located at 1851 Harbor Bay Parkway, Alameda, CA 94502, USA. Exelixis maintains communication through multiple channels with contact numbers (650) 837-7000; (650) 837-8300; (650) 837-8194; (650) 837-8205; (866) 214-2213; (888) 835-2555; (855) 292-3935; and (855) 500-3935. Their website can be accessed at exelixis.com, providing updates and informational resources to stakeholders. The company's business activities are recorded under Broward County with a Florida Filed Number F12000003676 and an FEI number of 043257395. As per the most recent annual report, filed on March 6, 2024, Exelixis continues its strategic initiatives in cancer therapy development. The organization is committed to advancing medical science to enable patients seeking improved treatment outcomes.